A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults

Current Oncology

Volumn 21, Issue 5, 2014, Pages 234-250

  Seftel, M D ^a   Schuh, A C ^a   Barnett, M J ^b   Couban, S ^c   Leber, B ^d   Storring, J ^e   Assaily, W ^f   Fuerth, B ^f   Christofides, A ^f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f New Evidence   (Canada)

Author keywords

Acute promyelocytic leukemia; Allogeneic transplantation; Apl; Arsenic trioxide; Ato; Autologous transplantation; First line treatment; Infusions; Management; Prophylaxis; Supportive care; Transplantation; Trisenox

Indexed keywords

ARSENIC TRIOXIDE; CREATININE; CYTARABINE; D DIMER; DAUNORUBICIN; FIBRINOGEN; FRESH FROZEN PLASMA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RECOMBINANT THROMBOMODULIN; RETINOIC ACID; VORICONAZOLE;

ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BLOOD CLOTTING DISORDER; CANADIAN; CANCER RECURRENCE; CONSENSUS; CONSOLIDATION CHEMOTHERAPY; CRYOPRECIPITATE; DISEASE FREE SURVIVAL; DISSEMINATED INTRAVASCULAR CLOTTING; EVENT FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPOFIBRINOGENEMIA; INFUSION; LEUKOCYTE DIFFERENTIAL COUNT; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84907806243     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.2183     Document Type: Article

References (51)

1. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009;114:5126-35.
2. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16:1959-73.
3. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011;29:495-503.
4. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Philos Trans R Soc Lond B Biol Sci 2007;362:959-71.
5. Tallman M, Lo-Coco F, Kwaan HC, Sanz M, Gore S. Early death in patients with acute promyelocytic leukemia. Proceedings from a live roundtable at the 2010 American Society of Hematology Annual Meeting, December 4-7, 2010, Orlando, Florida. Clin Adv Hematol Oncol 2011;9:1-16.
6. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-21.
7. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012;120:1570-80.
8. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875-91.
9. Park JH, Tallman MS. Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible? Expert Rev Hematol 2011;4:427-36.
10. Breccia M, Latagliata R, Cannella L, et al. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 2010;95:853-4.
11. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:1248-54.
12. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a populationbased report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011;25:1128-34.
13. McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012;97:133-6.
14. Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol 2014;:[Epub ahead of print].
15. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008;111:3395-402.
16. Marti-Carvajal AJ, Simancas D, Cardona AF. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev 2011;:CD008562.
17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Ver. 2.2013. Fort Washington, PA: NCCN; 2013. [Current version available online at: http://www.nccn.com/ files/cancer-guidelines/breast/index.html (free registration required); cited May 8, 2014]
18. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL group experience. J Clin Oncol 2009;27:2668-76.
19. Barreto JN, Kuth JC, Peskey CS, Patnaik MM. A comparative study of patients with acute promyelocytic leukemia receiving all-trans retinoic acid with and without voriconazole: effect on differentiation syndrome. Pharmacotherapy 2012;32:e178.
20. Chang H, Kuo MC, Shih LY, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol 2012;88:321-8.
21. Ikezoe T, Takeuchi A, Isaka M, et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leuk Res 2012;36:1398-402.
22. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
23. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
24. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010;116:3751-7.
25. Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010;28:1047-53.
26. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006;107:3469-73.
27. 3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 2003;97:2218-24.
28. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003;14:752-7.
29. Shigeno K, Naito K, Sahara N, et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005;82:224-9.
30. Lundbeck Canada. Trisenox (arsenic trioxide) [product monograph]. Montreal, QC: Lundbeck Canada; 2013.
31. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009;106:3342-7.
32. Liu YJ, Wu DP, Liang JY, et al. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients. Med Oncol 2011;28(suppl 1):S513-21.
33. Huang BT, Zeng QC, Gurung A, et al. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience. Med Oncol 2012;29:2088-94.
34. Menon H, Kumar S, Sengar M, et al. Sequential arsenic trioxide, and all trans retinoic acid with daunomycin yield early cytogentic and molecular response in newly diagnosed acute promyelocytic leukemia-data from a tertiary cancer centre [abstract 2628]. Blood 2012;120:. [Available online at https:// ash.confex.com/ash/2012/webprogram/Paper52514.html; cited August 14, 2014]
35. Ades L, Chevret S, Raffoux E, et al. Arsenic trioxide (ATO) or ATRA for consolidation treatment of standard risk non elderly newly diagnosed APL-second interim analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL Group [abstract 495]. Blood 2013:121:. [Available online at: https:// ash.confex.com/ash/2013/webprogram/Paper60074.html; cited August 13, 2014]
36. Lou Y, Qian W, Meng H, et al. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res 2013;37:37-42.
37. Dai CW, Zhang GS, Shen JK, et al. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients. Acta Haematol 2009;121:1-8.
38. Arora A, Malhotra P, Das R, Varma S, Suri V, Varma N. Safety and efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) combination therapy in acute promyelocytic leukemia [abstract 0648]. Haematologica 2010;95(suppl 2):272. [Available online at: http://online.haematologica.org/eha15/browserecord. php?-action=browse&-recid=6718; cited August 13, 2014]
39. Ravandi F, Estey EH, Cortes JE, et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL) [abstract 1080]. Blood 2010;116:. [Available online at: https://ash.confex.com/ash/2010/ webprogram/Paper29064.html; cited August 13, 2014]
40. Pei R, Cao J, Ma J, et al. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia. Hematology 2012;17:311-16.
41. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27:504-10.
42. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (Trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003;8:132-40.
43. Yanada M, Tsuzuki M, Fujita H, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood 2013;121:3095-102.
44. Fujita H, Asou N, Iwanaga M, et al. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. Cancer Sci 2013;104:1339-45.
45. Pemmaraju N, Tanaka MF, Ravandi F, et al. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 2013;13:485-92.
46. Ramadan SM, Di Veroli A, Camboni A, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. Haematologica 2012;97:1731-5.
47. Shepard DD, Kohrt HE, Rosenblat TL, et al. Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL [abstract 6619]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/84335-102; cited August 14, 2014]
48. Ferrara F, Finizio O, Izzo T, et al. Autologous stem cell transplantation for patients with acute promyelocytic leukemia in second molecular remission. Anticancer Res 2010;30:3845-9.
49. Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009;15:1479-84.
50. Linker CA, Owzar K, Powell B, et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 2009;44:353-9.
51. Holter Chakrabarty JL, Rubinger M, Le-Rademacher J, et al. Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission. Biol Blood Marrow Transplant 2014;20:1021-5.